A Retrospective Case Series Reporting the Clinical Efficacy and Adverse Events of Oclacitinib Administration for Skin Disease in 238 Cats
Veterinary Dermatology · 2026-08 · 37 (4) · 557-566
DOI: 10.1111/vde.70077 ↗Kurz gefasst
Fachartikel in der Zeitschrift Veterinary Dermatology, online erschienen am 26.04.2026. Verfasst von Marlyse R Wehber und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pet Dermatology Clinic, Maple Grove, Minnesota, USA. Hauptthemen laut MEDLINE: Pyrimidines, Cat Diseases, Sulfonamides, Skin Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Off‐label oclacitinib use for feline dermatoses management is increasing despite the paucity of data regarding optimal dose and adverse events (AEs).
Objective
Review AEs, clinical efficacy, and dose regimens in cats prescribed oclacitinib. Materials and Methods Retrospective case series of 238 privately owned cats prescribed oclacitinib for dermatological disease. Signalment, history, laboratory abnormalities, oclacitinib dosage (mg/kg/day), treatment duration and AEs using a modified Naranjo Adverse Drug Reaction Probability Scale were retrieved from medical records spanning August 2014 to May 2024. Clinical efficacy was estimated using a pruritus Visual Analogue Scale and medical record lesional descriptions; categorised as complete, partial or no response.
Results
The mean ( x̄ ) initial dosage prescribed was 1.89 mg/kg/day. Monotherapy controlled clinical signs in 140 of 238 cats (59%), including 83 of 140 cats (59%) on twice daily ( x̄ = 1.85 mg/kg/day) and 57 of 140 cats (41%) on once daily administration ( x̄ = 1.05 mg/kg/day). The median treatment duration was 271.5 days (range 1 day–7.5 years). Main diagnoses successfully managed included feline atopic skin syndrome (61%) and pemphigus foliaceus (29%). Thirty‐three ‘definite’ or ‘probable’ AEs were observed in 32 of 238 cats including: neutropaenia 6.3% ( n = 15), gastrointestinal 4% ( n = 9), lethargy 1.7% ( n = 4), infection 0.8% ( n = 2), hyperactivity 0.4% ( n = 1), elevated alanine transaminase 0.4% ( n = 1) and elevated creatinine 0.4% ( n = 1). Conclusions and Clinical Relevance Off‐label oclacitinib administration in cats appeared to be well‐tolerated and effective with AEs typically mild, responsive to dose reduction, and similar to those reported in dogs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pet Dermatology Clinic, Maple Grove, Minnesota, USA.
- Veterinary Clinical Sciences, University of Minnesota, Saint Paul, Minnesota, USA.
ORCID-Profile: Marlyse R Wehber, Amanda J Young, Sandra N Koch
Zitieren
APA
Wehber, M. R., Eisenschenk, M. C., Young, A. J., & Koch, S. N. (2026). A Retrospective Case Series Reporting the Clinical Efficacy and Adverse Events of Oclacitinib Administration for Skin Disease in 238 Cats. Veterinary Dermatology, 37(4), 557-566. https://doi.org/10.1111/vde.70077
Vancouver
Wehber MR, Eisenschenk MC, Young AJ, Koch SN. A Retrospective Case Series Reporting the Clinical Efficacy and Adverse Events of Oclacitinib Administration for Skin Disease in 238 Cats. Veterinary Dermatology. 2026;37(4):557-566. doi:10.1111/vde.70077
BibTeX
@article{Wehber2026,
author = {Wehber, Marlyse R and Eisenschenk, Melissa C and Young, Amanda J and Koch, Sandra N},
title = {A Retrospective Case Series Reporting the Clinical Efficacy and Adverse Events of Oclacitinib Administration for Skin Disease in 238 Cats},
journal = {Veterinary Dermatology},
year = {2026},
volume = {37},
number = {4},
pages = {557--566},
doi = {10.1111/vde.70077}
}
EUVIMED